Connection

Andrew Kraft to Prostatic Neoplasms, Castration-Resistant

Back to Details
This is a "connection" page, showing publications Andrew Kraft has written about Prostatic Neoplasms, Castration-Resistant.
Andrew Kraft
Connection Strength
0.108
Prostatic Neoplasms, Castration-Resistant
  1. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53.
    View in: PubMed
    Score: 0.108
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.